Treatment-resistant depression: An update on diagnosis and management

Psychopharm Review

Volumn 44, Issue 6, 2009, Pages 41-48

  Janicak, Philip G ^a   Dowd, Sheila M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMFEBUTAMONE; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; ESCITALOPRAM; FLUOXETINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE; ZIPRASIDONE;

AGITATION; AKATHISIA; ALCOHOLISM; ALTERNATIVE MEDICINE; ANHEDONIA; ANXIETY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLURRED VISION; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FATIGUE; FUNCTIONAL STATUS; HAMILTON SCALE; HEADACHE; HUMAN; HYPOMANIA; INCREASED APPETITE; INSOMNIA; MAJOR DEPRESSION; MELANCHOLIA; METABOLIC DISORDER; NEUROMODULATION; OBSESSIVE COMPULSIVE DISORDER; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOMOTOR ACTIVITY; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; RESTLESSNESS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; SUSTAINED DRUG RELEASE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESISTANCE DEPRESSION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; WEIGHT GAIN; XEROSTOMIA;

EID: 77955602602     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.IDT.0000350191.07142.ef     Document Type: Review

References (42)

1. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 2008;300(18):2161- 2171.
2. Frasure-Smith N, Lesperance F. Depression and anxiety as predictors of 2- year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 2008;65(1):62-71.
3. Gorwood P, Corruble E, Falissard B, et al. Toxic effects of depression on brain function: Impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008;165;731-739.
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCSR). JAMA 2003;289:3095-3105.
5. Gilmer WS, Gollan JK, Wisniewski SR, et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? a STAR*D Report. J Clin Psychiatry 2008;69:1246-1256.
6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242.
7. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: A meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008;63:699-704.
8. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006;67:688-695.
9. Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(Suppl 13):23-29.
10. Souery D, Amsterdam J, de Montigny C, et al. Treatment-resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91.
11. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659.
12. Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry 2007;64(8):903-912.
13. Rothschild AJ, Winer J, Flint AJ, et al. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry 2008;69:1293-1296.
14. Vythilingam M, Chen J, Bremmer JD, et al. Psychotic depression and mortality. Am J Psychiatry 2003;160:574-576.
15. McGrath PJ, Khan AY, Trivedi MH, et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry 2008;69:1847-1855.
16. Gilmer WS, Kemp DE. STAR*D: What have we learned thus far? Int Drug Ther Newsl 2006;41(10):75-82.
17. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008;65(8):870-881.
18. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172. (Pubitemid 44464443)
19. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypro mine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1531-1541.
20. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007;164(5):739-752.
21. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, openlabel, pilot study. J Clin Psychiatry 2007;68:1071-1077.
22. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-853.
23. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. J Clin Psychopharmacol 2008;28(2):156-165.
24. Earley W, McIntyre A, Bauer M, et al. Efficacy and tolerability of extended release quetiapine furmarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD): results from a double-blind, randomized Phase III study. Presented at the 46th American College of Neuro - psychopharma cology annual meeting, Boca Raton, Fla., December 9-13, 2007.
25. Khalili NE, Joyce M, Atkinson S, et al. Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response. Pre sented at the 161st annual meeting of the American Psychiatric Association, Washington, DC, May 3-8, 2008.
26. Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavioral therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008;8:73.
27. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43(3):205-214.
28. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatmentrefractory major depressive disorder: a randomized trial. Ann Intern Med 2007;147(9):593-602.
29. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-1236.
30. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-236.
31. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354(12):1243-1252.
32. Harley R, Sprich S, Safren S, et al. Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. J Nerv Ment Dis 2008;196(2):136-143.
33. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163;9:1519-1530. (Pubitemid 44465751)
34. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or venlafaxine with or without CBT for adolescents with SSRI-resistant depression: the TORDIA randomized, controlled trial. JAMA 2008;299(8):901-913.
35. Pierce K, Flynn P, Caudle M, et al. Electroconvulsive therapy: current clinical standards. Psychopharm Rev 2008;43(5):35-42.
36. Pilitsis JG, Bakay RAE. Deep brain stimulation for psychiatric disorders. Psychopharm Rev 2007;42(9):67-74.
37. Rado JT. Vagus nerve stimulation for treatment-resistant depression. Int Drug Ther Newsl 2006;41(6):41-50.
38. Dowd SM, Janicak PG. Transcranial magnetic stimulation for major depression: part I. Int Drug Ther Newsl 2006;41(11):83-90.
39. Dowd SM, Janicak PG. Transcranial magnetic stimulation for major depression: part II. Int Drug Ther Newsl 2007;42(1):1-8.
40. O'Reardon JP, Solvason B, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208-1216.
41. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of ma jor depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009;34(2):522-534.
42. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry 2008;69(2):222-232.